CytoReason, an Israeli startup that offers AI-enabled tools for life sciences companies, secured $80 million in funding from Pfizer, OurCrowd, NVIDIA, and Thermo Fisher Scientific. The company’s computation model provides insights into datasets, cell states, disease progression, and treatment effects. They plan to expand their models for different indications, grow their data, and open an office in Cambridge, Massachusetts. Pfizer collaborates with CytoReason to enhance drug development pathways. Other companies like EvolutionaryScale and Google are also using AI for drug discovery. Google’s Tx-LLM shows promise as an end-to-end therapeutic development assistant.
Source link
Israeli startup CytoReason raises $80M to expand AI model, open hub in Massachusetts
